NASDAQ
0.39USD
-0.07 (-15.22%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
163.4K
P/E
—
EPS
—
Beta
-0.25
52W range
0.39-80
Day range
0.39–0.42
Open
0.41
Prev close
0.46
Volume
390.1K
Avg volume
660.1K
Dividend
0.00
IPO
2024-08-16
https://www.globenewswire.com/news-release/2026/08/14/3345339/0/en/silexion-therapeutics-reports-second-quarter-2026-financial-results-and-provides-business-update.html · 8/14/2026+0.80
https://www.globenewswire.com/news-release/2026/06/23/3315982/0/en/Silexion-Therapeutics-Receives-Approval-from-Germany-s-BfArM-to-Initiate-Phase-2-3-Clinical-Trial-of-SIL204-in-Locally-Advanced-Pancreatic-Cancer.html · 6/23/2026+1.00
https://www.globenewswire.com/news-release/2026/04/28/3282684/0/en/Silexion-Therapeutics-Announces-Successful-Submission-of-Phase-2-3-Clinical-Trial-Application-to-Germany-s-BfArM-for-SIL204-in-KRAS-Driven-Locally-Advanced-Pancreatic-Cancer.html · 4/28/2026+0.80
https://www.globenewswire.com/news-release/2025/11/12/3186310/0/en/Silexion-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html · 11/12/2025
https://www.benzinga.com/news/health-care/25/09/47627634/silexion-therapeutics-shares-surge-on-positive-preclinical-pancreatic-cancer-data · 9/11/2025+1.00
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
